MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35106515.
- Also identified by DOI 10.1016/j.xcrm.2021.100506 and PMC identifier 8784763.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A recent study by Limagne et al.<sup>1</sup> in <i>Cancer Cell</i> demonstrates that addition of MEK inhibitor to standard-of-care platinum/pemetrexed promotes mitophagy-dependent CXCL10 expression via optineurin and TLR9. Tumor cell secretion of CXCL10 produces T cell recruitment and enhances immunotherapy efficacy.
Medical subject headings
- Mitophagy
- Neoplasms